Is it correct to report code 78803 , Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); tomographic (SPECT), for SPECT and/or SPECT/CT parathyroid studies? ...
Subscribe or sign in to view the full article.
Article Overview
This article addresses a coding question about how to report parathyroid imaging studies in nuclear medicine, with discussion centered on SPECT and SPECT/CT workflows. It is written for coding professionals, auditors, and billing teams who need to understand the scope of the guidance and the code families involved without exposing the premium-level rationale.
Why This Topic Matters
Correctly identifying the applicable imaging code family affects accurate claim reporting and reduces the risk of using a code that does not match the study performed.
What You Will Learn
- The general issue raised for parathyroid imaging studies involving SPECT and SPECT/CT.
- How the article frames the distinction between related nuclear medicine reporting options.
- Which code families are discussed in relation to these studies.
- The type of coding question the article answers for billing and documentation review.
Who Should Read This
- Medical coders
- Coding auditors
- Hospital outpatient billing staff
- Radiology and nuclear medicine reimbursement teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com